Deal Watch: Seattle Genetics And Genmab Partner Again On Anti-Cancer ADC
MabVax to provide antibody-targeting technology to Memorial Sloan-Kettering, which could yield CAR-T therapeutic candidates for which Juno Therapeutics will hold an exclusive option. Mylan acquires injectable anticoagulant Arixtra from Aspen for $300 million, while Asterias will work with Cancer Research UK on non-small cell lung cancer program.
You may also be interested in...
Deal Watch: Infinity Scores With AbbVie Deal, AbbVie Tries New Angle With Calico
Infinity gains street cred with AbbVie partnership on duvelisib, while AbbVie also branches out into aging disease by obtaining a stake in Google’s Calico; Palatin and Gedeon Richter pair up on female sexual dysfunction; and AstraZeneca finds an oncology discovery engine in Redx.
Spinal Cord Injury Product Makes Progress As Asterias Picks Up Where Geron Left Off
New endpoint guidelines – and matching grant funding from the California Institute for Regenerative Medicine – enhance possibility of demonstrating functional improvement in the Phase I/IIa trial of the stem-cell therapeutic.
AstraZeneca, Pfizer, U.K. Charity’s Joint Lung Cancer Trial Aims To Make Tumor Genetic Testing Routine
A pioneering approach to trialing targeted medicines in late-stage NSCLC is being launched throughout Britain, giving researchers unprecedented access to libraries of drugs developed by AstraZeneca and Pfizer, allowing several to be tested at the same time within one trial.